Neuronetics (NASDAQ:STIM) Announces Earnings Results, Beats Expectations By $0.07 EPS

Posted by Francis Steltz on Aug 12th, 2026

Neuronetics (NASDAQ:STIM – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.07, FiscalAI reports. Neuronetics had a negative return on equity of 139.83% and a negative net margin of 24.48%.The firm had revenue of $41.57 million during the quarter, compared to analysts’ expectations of $40.17 million.

Here are the key takeaways from Neuronetics’ conference call:

Revenue rose 9.1% to $41.6 million, while adjusted EBITDA improved to positive $0.3 million from negative $5.6 million a year ago. Net loss narrowed to $3.4 million, and cash used in operations and investing fell to $1.4 million.
Greenbrook revenue increased 16.8% to $26.9 million, supported by provider growth, improved reimbursement and revenue-cycle management. Management said cash collections grew faster than revenue and identified further upside from increasing clinic occupancy, with roughly 40% of capacity still unused.
Neuronetics is broadening NeuroStar’s commercial model to include outright purchases, lease financing and à la carte support alongside its traditional treatment-session model. Capital sales grew double digits, but session revenue declined double digits; management expects some near-term revenue volatility as customers shift among models.
The company raised its full-year gross-margin outlook to 48%–50% and lowered operating-expense guidance to $95 million–$100 million, while narrowing revenue guidance to $160 million–$164 million. It expects cash flow from operations and investing of negative $10.5 million to negative $14.5 million for the year and limited net cash use in the second half.
Management continues preparing Greenbrook for potential psychedelic treatment launches, particularly Compass Pathways’ COMP360, leveraging existing SPRAVATO infrastructure, trained staff and available clinic capacity. The company views its combination of TMS, SPRAVATO and future therapies as a potential differentiator in interventional psychiatry.

Neuronetics Trading Up 47.0%

STIM stock opened at $3.19 on Wednesday. The company has a market cap of $221.99 million, a P/E ratio of -5.91 and a beta of 1.03. Neuronetics has a twelve month low of $0.80 and a twelve month high of $4.00. The company has a quick ratio of 1.50, a current ratio of 1.67 and a debt-to-equity ratio of 3.59. The business has a fifty day moving average of $1.65 and a 200-day moving average of $1.56.

Analyst Ratings Changes

A number of analysts have recently weighed in on STIM shares. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, June 18th. BTIG Research upped their price target on shares of Neuronetics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Neuronetics in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $4.50.

View Our Latest Research Report on STIM

Insider Transactions at Neuronetics

In other news, major shareholder Jorey Chernett purchased 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average price of $1.17 per share, for a total transaction of $117,000.00. Following the completion of the acquisition, the insider directly owned 10,553,988 shares in the company, valued at approximately $12,348,165.96. The trade was a 0.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in STIM. UBS Group AG boosted its stake in Neuronetics by 580.7% during the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock worth $5,910,000 after acquiring an additional 1,846,801 shares during the last quarter. Lane Generational LLC bought a new stake in Neuronetics during the 4th quarter worth approximately $2,353,000. Goldman Sachs Group Inc. increased its stake in Neuronetics by 2,993.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after purchasing an additional 610,014 shares in the last quarter. Geode Capital Management LLC raised its holdings in Neuronetics by 172.3% during the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock worth $3,068,000 after buying an additional 556,268 shares during the period. Finally, Wexford Capital LP raised its holdings in Neuronetics by 83.1% during the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock worth $3,214,000 after buying an additional 534,155 shares during the period. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Key Neuronetics News

Here are the key news stories impacting Neuronetics this week:

Positive Sentiment: Q2 results exceeded expectations: Neuronetics reported a loss of $0.05 per share, narrower than the $0.11–$0.12 analyst consensus, while revenue rose 9.1% year over year to $41.6 million, above estimates of approximately $40.2 million. Neuronetics Q2 earnings report
Positive Sentiment: Profitability improved substantially: Adjusted EBITDA turned positive at $0.3 million, compared with a $5.6 million loss a year earlier. Net loss narrowed to $3.4 million from $10.1 million, helped by a 12% reduction in operating expenses and gross-margin expansion to 51.1%. Neuronetics second-quarter financial results
Positive Sentiment: Greenbrook drove growth: Revenue from the Greenbrook clinic network increased 16.8% to $26.9 million, more than offsetting a 2.7% decline in NeuroStar revenue. Management also highlighted new leadership appointments and efforts to improve NeuroStar’s go-to-market strategy. Neuronetics Q2 results and operational update
Positive Sentiment: Analyst sentiment strengthened: BTIG Research raised its price target from $5 to $6 and assigned a “Buy” rating, implying substantial potential upside from the reference price. BTIG price-target update
Neutral Sentiment: 2026 outlook was refined: Revenue guidance is now $160 million to $164 million, versus the previous $160 million to $166 million range and roughly in line with consensus. The company raised its gross-margin outlook to 48%–50% and lowered projected operating expenses to $95 million–$100 million.
Negative Sentiment: Cash and profitability remain risks: Neuronetics still expects negative 2026 cash flow from operations and investing of $10.5 million to $14.5 million. Cash declined to approximately $25 million at June 30, and the company remains unprofitable with significant debt and interest expense.

About Neuronetics

(Get Free Report)

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.